Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430963
Status:
COMPLETED
Last Update Posted:
2011-10-26
First Post:
2007-02-01
Brief Title:
IncobotulinumtoxinA Xeomin Versus Placebo in the Treatment of Glabellar Frown Lines
Sponsor:
Merz Pharmaceuticals GmbH
Organization:
Merz Pharmaceuticals GmbH
Study Overview
Official Title:
A Prospective Randomized Double-blind Placebo-controlled Multicenter Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of IncobotulinumtoxinA Xeomin Free of Complexing Proteins in the Treatment of Glabellar Frown Lines
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
IncobotulinumtoxinA Xeomin is a botulinum toxin type A preparation free of complexing proteins ie free of proteins other than the active toxin Injected into the muscle IncobotulinumtoxinA Xeomin causes local weakening Botulinum toxin type A is widely used for aesthetic treatment of facial lines This study investigated the efficacy and safety of IncobotulinumtoxinA Xeomin in the treatment of glabellar frown lines compared to placebo The study consisted of a Main Period and an Open-Label Extension OLEX Period of 120 days each
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None